Zacks Investment Research reaffirmed their sell rating on shares of Xencor (NASDAQ:XNCR) in a research report released on Saturday morning.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

A number of other equities research analysts have also recently issued reports on XNCR. ValuEngine cut Xencor from a hold rating to a sell rating in a report on Monday, October 23rd. BidaskClub cut Xencor from a sell rating to a strong sell rating in a report on Friday, December 15th. Piper Jaffray Companies restated a buy rating and set a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Cantor Fitzgerald began coverage on Xencor in a report on Wednesday, November 29th. They set an overweight rating and a $33.00 price objective for the company. Finally, Canaccord Genuity set a $36.00 price objective on Xencor and gave the stock a buy rating in a report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Xencor presently has an average rating of Hold and an average price target of $30.80.

Shares of Xencor (NASDAQ XNCR) traded down $0.26 during trading hours on Friday, hitting $22.50. The stock had a trading volume of 102,065 shares, compared to its average volume of 158,150. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64.

In related news, major shareholder John S. Stafford III purchased 50,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was acquired at an average cost of $19.58 per share, for a total transaction of $979,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder John S. Stafford III purchased 24,653 shares of the business’s stock in a transaction that occurred on Wednesday, October 25th. The stock was bought at an average price of $20.01 per share, with a total value of $493,306.53. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 278,535 shares of company stock valued at $5,526,936. 4.03% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. Virginia Retirement Systems ET AL boosted its stake in shares of Xencor by 10.0% in the third quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock valued at $1,747,000 after buying an additional 6,900 shares during the period. State Street Corp boosted its stake in shares of Xencor by 11.1% in the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after buying an additional 110,474 shares during the period. Vanguard Group Inc. boosted its stake in shares of Xencor by 5.6% in the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after buying an additional 90,094 shares during the period. Northern Trust Corp boosted its stake in shares of Xencor by 6.6% in the second quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock valued at $10,527,000 after buying an additional 30,715 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in shares of Xencor by 87.4% in the third quarter. GSA Capital Partners LLP now owns 72,700 shares of the biopharmaceutical company’s stock valued at $1,666,000 after buying an additional 33,900 shares during the period. Institutional investors and hedge funds own 77.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2018/01/14/xencor-xncr-earns-sell-rating-from-zacks-investment-research.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.